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Psoriasis is associated with being overweight, but the 
temporal relationship is not known. This historical co-
hort study tested whether severe psoriasis resulting in 
hospitalization in adulthood was preceded by excess 
increase in age-adjusted body mass index, a known 
risk factor in childhood for being overweight in adult-
hood. The study cohort was based on the Copenhagen 
School Health Records Register, birth years 1930 to 1984 
(309,152 schoolchildren). Cases were found through the 
Danish National Patient Register for the period 1977 to 
2001. A total of 1074 (0.36%) of the schoolchildren were 
identified as having psoriasis, with at least one hospital 
admission. Multivariate analysis demonstrated an as-
sociation between excess increase in body mass index 
and psoriasis in females only. Being overweight in adole-
scence was the main factor behind this observation. The 
female group showed a significant association between 
psoriasis and body mass index at ages 12 (p = 0.028) and 
13 years (p = 0.010). This was not the case for males or for 
body mass index measured at ages 11 years and below. 
Key words: psoriasis BMI; historical cohort; linkage re-
cord; epidemiology.
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Psoriasis is associated with being overweight and with 
metabolic syndrome. Several cross-sectional studies 
have demonstrated this association in adulthood, both 
regarding incidence and clinical severity (1–4). Ad-
ditionally, it has been noted that patients with psoriasis 
who are eligible for biological treatment generally were 
more overweight than the normal population (5, 6). The 
causal relationship remains elusive, as obesity may be 
both a cause of and a consequence of having psoriasis. 
It has been hypothesized previously that psycho-social 
stigma may lead to secondary obesity in psoriasis pa-
tients, but obesity as such is currently regarded as a pro-
inflammatory state (7) that may hypothetically be able 
to alter inflammatory disease according to individual 
predisposition (8). 
Two previous studies have tried to elucidate a pos-
sible temporal relationship between being overweight 
and psoriasis. One study (9) collected information about 
body mass index (BMI; kg/m2) at onset of psoriasis and 
compared it with BMI at 18 years of age as recalled by 
the patients. The conclusion was that psoriasis seemed 
to precede being overweight, but recall bias was ack-
nowledged in the discussion part of the paper. Another 
study (10) prospectively examined BMI in nurses from 
the age of 25 years and retrospectively collected inci-
dent cases of self-reported psoriasis during the 14-year 
follow-up period as well as BMI at the age of 18 years. 
This study, in contrast, clearly demonstrated that being 
overweight at the age of 18 years was followed by larger 
incidences of psoriasis in the follow-up period. A lower 
BMI was also associated with a reduced incidence of 
psoriasis. More studies of the temporal relationship 
between being overweight and psoriasis have recently 
been requested (11).
Being overweight in childhood is associated with 
being overweight later in life, but not strongly so. Being 
overweight in late childhood and weight fluctuations 
during childhood seem to be the strongest predictors 
for being overweight in adulthood (12).
The aim of the present study was to test whether severe 
psoriasis (defined as resulting in hospitalization in adult-
hood) could be predicted by risk factors for adult obesity, 
such as weight fluctuations and weight increase during 
childhood. Traditionally, only moderate to severe cases 
of psoriasis have been referred to hospital treatment in 
Denmark. Of these, only the most severe were admitted 
for inpatient care. Milder cases have been maintained in 
private practice or as hospital outpatients. 
METHODS
School health report data from all schoolchildren attending 
primary school within the municipality of Copenhagen were 
available for the study through the Copenhagen School Health 
Records Register (13). This historical cohort was defined as 
all children born between 1930 and 1984 with data available 
on weight and height in the age group 7–13 years. The total 
number of schoolchildren was 309,152. From these data we 
calculated the age-specific BMI for each pupil. Deviations from 
reference BMI z-scores were calculated based on the age- and 
sex-matched normal BMI distribution in children born in the 
period 1955 to 1960 (14). Before the start of the study we con-
High Body Mass Index in Adolescent Girls Precedes Psoriasis 
Hospitalization
Lars Erik BRyLD1, Thorkild I. A. SøRENSEN2, Klaus Kaae ANDERSEN3, Gregor B. E. JEMEC1 and Jennifer L. BAKER2
1Department of Dermatology, Roskilde Hospital, Roskilde, 2Section of Statistics, Technical University of Denmark, Informatics, and 3Institute of Preventive 
Medicine, University of Copenhagen, Copenhagen, Denmark
489High BMI in adolescence precedes psoriasis in women
sidered excess growth of BMI, and fluctuations in BMI during 
childhood as possible risk indicators for being overweight in 
adulthood and, according to our hypothesis, consequently also 
for psoriasis. Growth could not be estimated for schoolchildren 
with only one height-weight measurement available (n = 8768). 
Through their social security numbers (unique person identi-
fiers) schoolchildren were cross-linked to all patients who were 
registered within the National Patient Register with a diagnosis 
of psoriasis (ICD-8 code 696.19 or ICD-10 code L40.0-L40.9) 
in the period 1977 to 2001. The National Patient Register under 
the National Board of Health contains all hospital inpatient 
admissions in Denmark from 1977, and in all cases at least one 
diagnosis was registered at discharge. 
Statistical analysis
Only cases with two or more height-weight measurements at 
different ages were included in our analysis in order to be able to 
estimate increase in BMI during childhood. A linear regression 
model was fitted for each case to estimate the temporal deve-
lopment in z-scores for BMI. The estimated intercept and slope 
(for each individual), together with gender and year of birth, was 
then included as a covariate in a multivariate logistic regression 
model. The effect of the individual slope was tested in order 
to evaluate whether excess growth in BMI during childhood 
was associated with moderate to severe psoriasis, defined as 
inclusion into the National Patient Register with a diagnosis of 
psoriasis because of an episode of hospitalization. Significance 
of predictors was based on the likelihood ratio test. All variables 
were kept in the model if significant at the 5% level.
In accordance with the pre-planned outcome expectations, 
we also tested a possible effect of variability in BMI on pso-
riasis. All analyses were repeated on the 80% subset with all 
7 possible measurements, and additionally on the same subset 
after discarding values for the ages 8, 10 and 12 years. This 
was done in order to test for possible effect of outliers and of 
data interdependency.
In a subsequent analysis, age- and gender-specific z-scores 
for BMI was compared for the psoriasis-yes group with the 
psoriasis-no using two-sided t-tests. All analyses were perfor-
med using the statistical software R (15).
RESULTS
The database consisted of 300,384 schoolchildren with 
at least two height-weight measurements. Approxima-
tely 80% of these had all seven measurements possible 
for ages 7–13 years. From the National Patient Register 
1074 (0.36%) of the schoolchildren were identified 
as psoriasis patients, with slightly more male than 
female patients (593/152051 vs. 481/148333). The 
schoolchildren’s years of birth followed the national 
demographic trend, with a comparatively high number 
born in 1930, peaking in 1945, and declining towards 
1980. Patient cases reflected the same pattern (Fig. 1). 
A multivariate analysis was designed to test the 
primary hypothesis that excess gain in BMI during 
childhood (expressed as the individual slope in temporal 
BMI development for each person) might be associa-
ted with psoriasis. The median BMI z-score at age 10 
years was initially chosen as the intercept, because of 
its position in the middle of our observation range. In 
this analysis an association was found between excess 
BMI gain during childhood and psoriasis in females, 
but not in males (Fig. 2).
In order to further validate this result, the model 
was changed in such a way that the BMI z-score at 13 
years of age was used as the intercept instead. This 
modification of the model, however, annulled the 
observed effect of excess BMI-gain in females. That 
observation strongly suggests that the effect observed 
should be attributed to a higher BMI at age 13 years 
rather than to the excess BMI-gain as such, and this 
was confirmed by including the BMI z-score at age 13 
in the multivariate analysis. Checking for variability 
in BMI, as described above, did not alter the results 
in any way.
In accordance with this, age-specific z-scores for 
BMI did not show any significant differences between 
psoriasis patients and non-patients and not in the male 
subgroup either. The female group, however, showed a 
significant association between psoriasis and BMI ex-
pressed as z-scores at ages 12 and 13 years (Table I).
The most important finding in the study thus ap-
peared to be a marked effect in females on psoriasis 
from BMI expressed as z-score in early adolescence 
with an odds ratio for one unit increase in z-score of 
BMI at age 13 years of 1.49 (95% CI 1.19–1.86). The 
effect in males was not significant, with an odds ratio 
for one unit increase in z-score of BMI at age 13 years 
of 0.87 (95% CI 0.68–1.10). This is illustrated in Fig. 
2 by year of birth.
DISCUSSION
This historical cohort study demonstrates an increased 
risk of admission to hospital for psoriasis in females 
relating to increased BMI at age 12 and 13 years. The 
increased risk can be expressed as an increase of 1.49 
in odds-ratio for each unit increase in z-score of BMI. 
A similar effect was, however, not found in males, and 
the original hypotheses regarding effects from excess 
Fig. 1. Cumulative incidence of psoriasis as a function of temporal development 
of z-scores of body mass index (BMI). A significant association (p < 0.001) 
is found for females, but not for males.
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growth in BMI during childhood or excess BMI in early 
childhood were not confirmed.
The study benefits from a substantial amount of data, 
which were collected in a very systematic way for other 
purposes over a long period of time. The present data on 
over 300,000 persons exhaustively and systematically 
examined over several years within a well-defined area 
strengthens the validity of our findings.
Psoriasis patients have demonstrated a high level 
of inflammatory mediators, such as tumour necrosis 
factor (TNF)-α and interleukin (IL)-6, which is also 
characteristic of patients who are overweight and those 
with metabolic syndrome (16). Additionally, the satiety 
hormone leptin has been demonstrated to promote 
TNF-α and other immunoregulators (17). This supports 
the hypothesis that being overweight might provoke or 
worsen psoriasis.
Neither adult psoriasis nor metabolic syndrome ge-
nerally show sex-differences in prevalence rates, but 
one previous study has found increased BMI in female 
same-gender siblings of psoriasis patients (18). A pos-
sible explanation might be hidden in the observation 
that adolescent weight in our study appeared to be more 
important with respect to psoriasis than early childhood 
weight development. If any weight gain is important for 
psoriasis; and if this in some way is connected with onset 
of puberty (something that would have happened in the 
great majority of girls but in only a fraction of the boys 
at ages 12 and 13 years (19)) then an assumed similar 
association between psoriasis and being overweight in 
adolescence in males may also exist, but we could not 
investigate this because of the later onset of puberty.
Some support for our observation may also be found 
in the sex-ratio in childhood psoriasis. The prevalence 
of psoriasis is generally thought to be equal between the 
sexes, but earlier reports have suggested that girls are 
more often treated for the disease than boys (20, 21). 
These reports may, on the other hand, also reflect more 
psychosocial aspects of the disease (22).
Another obvious aspect of a possible peri-menarchal 
increase in the prevalence of psoriasis is the increased 
level of sex hormones, in particular oestrogens, which 
are known to promote keratinocyte proliferation via spe-
cific receptor-mediated mechanisms (23–31). This me-
chanism appears to be significant in the wound-healing 
process, suggesting that this effect alone may provide 
a significant stimulus to the development of epidermal 
hypertrophy characteristic of psoriasis (32, 33).
Sex hormones are also known broadly to influence 
inflammation (34–37). The increased levels of oestrogen 
Table I. Age- and gender-specific z-scores for body mass index (BMI). The p-values are obtained from two-sided t-tests comparing the 
psoriasis-No group with the psoriasis-Yes group for each age and gender combination
Age, years
Psoriasis in males Psoriasis in females
No yes Difference p-value No yes Difference p-value
7 0.028 −0.001 0.029 0.457 0.004 0.029 −0.025 0.568
8 0.053 0.046 0.007 0.851 0.043 0.094 −0.051 0.257
9 0.051 0.068 −0.017 0.662 0.050 0.092 −0.042 0.352
10 0.048 0.061 −0.013 0.753 0.055 0.073 −0.018 0.687
11 0.048 0.052 −0.003 0.939 0.051 0.082 −0.031 0.467
12 0.059 0.050 0.009 0.822 0.061 0.161 −0.100 0.028
13 0.076 0.062 0.014 0.729 0.084 0.205 −0.120 0.010
Fig. 2. Cumulative incidence of psoriasis as a function of BMI at age 13 
years for female (top) and male (bottom) by year of birth. The curves denotes 
psoriasis incidence in persons with average BMI at age 13 (z = 0), moderately 
obese persons (z = 1.5) and severly obese persons (z = 3). The association is 
not significant for males, but is significant for females (p < 0.001).
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at menarche may influence the Th1 and Th2 immune 
responses through cytokines and chemokines, including 
monocyte chemoattractant protein-1 (MCP-1) produc-
tion (38–41). These changes may stimulate both the 
cellular activity and TNF-alpha-induced inflammatory 
response, potentially providing a more direct link to 
the pathophysiology of psoriasis similar to the situation 
seen in rheumatoid arthritis, and in direct contrast to, 
for example, systemic lupus erythematosus (42–45). 
Looking at the clinical presentation of the disease, it 
may therefore be suggested that oestrogens aggravate 
psoriasis (46), while anti-oestrogens may ameliorate 
it (47, 48).
Great care must, of course, always be taken with the 
interpretation of findings in any study of this kind. The 
number of registered psoriasis cases in this study is 
probably much smaller than the number of actual cases. 
The reasons for this are that the youngest participants 
were only followed up from 1984 to 2001, and cases 
diagnosed prior to the introduction of the National Pa-
tient Register in 1977 were not included if they were 
not admitted after 1977. As the oldest participants 
were born in 1930, some may have died, emigrated or 
been in remission from psoriasis before being able to 
be registered.
Psoriasis was, at that time, one of the most common 
admission diagnoses in dermatology wards, despite the 
fact that only a minority of all psoriasis patients was 
treated as inpatients (49). 
Psoriasis inpatients would have significantly more se-
vere clinical manifestations compared with outpatients 
(49). Furthermore, these patients would all have been 
referred from dermatology specialists in private prac-
tice, and thus qualified as more difficult or severe cases. 
However, no systematic bias in the coding is likely; and 
the inaccuracies were not considered to be significant, in 
view of the fact that only a small fraction of all psoriasis 
cases would in any case be expected to be subject to 
treatment in a hospital. The study population therefore 
invariably contains many false non-cases, and therefore 
no attempt at evaluating the prevalence, incidence or 
age of onset has been made. The number of dermato-
logical hospital beds has decreased steadily over time, 
including the observation period in the present study. In 
consequence, it has only been possible to admit the most 
severe cases of skin disease for inpatient care. The pre-
sent study was, by design, restricted to cases admitted 
as inpatients, and while these may include some milder 
cases in the beginning of the observation period in ad-
dition to the severe cases mainly admitted later on, a 
possible bias introduced by this should in all probability 
detract from the likelihood of noticing the presented 
association rather than facilitate it. Changes over time 
in admission thresholds is an important problem, but 
we have solved this by making all comparisons by BMI 
levels within birth cohorts, i.e. cohort-specific as it ap-
pears clearly from Fig. 1. This should remove most of 
the possible biases that may derive from the changes 
over time in admission practice. There may be a bias due 
to admission rates possibly being dependent on degree 
of obesity in adults, which is correlated with childhood, 
but this correlation is not strong, and if there had been 
such bias mechanism, we would have expected it to 
operate similarly in the two genders.
Onset of psoriasis can be seen in all age groups, but 
the most frequent age of onset is between 20 and 30 
years (50, 51), and approximately 75% of psoriasis 
patients are under 40 years of age (50, 52). In addition, 
the age of onset is regarded as biphasic, having an ad-
ditional peak incidence between 50 and 60 years of 
age (50, 53, 54). Cases with familial clustering tend to 
have an earlier age of onset (55, 56), and one study has 
observed self-reported age of onset before 16 years in up 
to one-third of all psoriasis patients, though the finding 
has not been verified in population-based studies, such 
as the classic 1948 Faroese study (57). Interestingly, a 
recent study has confirmed a link between overweight 
and childhood-onset psoriasis (58). The assumption 
that being overweight precedes psoriasis is dependent 
on the presupposition that age of psoriasis onset in 
our study does not differ systematically from what has 
been previously reported. As age at registration in this 
study is, in most cases, different from the patients’ true 
age of onset, our data does not permit us to test for this 
presupposition, and the apparent decline in incidence 
by year of birth is probably artificial.
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